- Home
- TWIN vs XFOR Comparison
TWIN vs XFOR Comparison
Compare TWIN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWIN | XFOR |
|---|---|---|
| Founded | 1918 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 276.3M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | TWIN | XFOR |
|---|---|---|
| Price | $17.61 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $28.50 |
| AVG Volume (30 Days) | 53.9K | ★ 475.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $340,738,000.00 | N/A |
| Revenue This Year | $10.79 | $1,263.94 |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $11.73 | ★ N/A |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $6.16 | $0.17 |
| 52 Week High | $19.63 | $6.63 |
Technical Indicators
Market Signals| Indicator | TWIN | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 42.95 |
| Support Level | $14.95 | $3.18 |
| Resistance Level | $18.91 | $3.77 |
| Average True Range (ATR) | 1.04 | 0.24 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 46.84 | 44.44 |
Price Performance
Historical ComparisonAbout TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.